News
03 May 2011
EU
Asthma , COPD

Virtual lung models set to personalise asthma and COPD treatment

World Asthma Day 2011 (3 May) - A team of international experts are set to develop a pioneering tool to help tailor the treatment of asthma and chronic obstructive pulmonary disease (COPD) as part of a new EU project.

The 5-year AirPROM* project, which is being launched this month (May 2011), will create computed and physical models of the whole airways system, to help scientists and doctors predict how patients might react to different treatments.

The news comes on World Asthma Day (3 May 2011), which aims to raise awareness about asthma and improve asthma care throughout the world.

Damaged, inflamed or obstructed airways are common in people with COPD and asthma, which makes breathing difficult. The current methods to detect and treat these conditions do not always consider individual differences in the airways that make each person unique. As a consequence, people with these conditions may not receive the most effective treatment.

Whilst scientists are working on more advanced, targeted approaches to treatment, they have often been unable to match these treatments to the right patients and explain the reasons behind this until now.

The AirPROM research team, which involves scientists from over 10 European countries, will make a computed model of the cells in an airway and a physical model of the airways, to assess how air flows through the lungs and why it becomes obstructed in people with asthma and COPD.

By using these unique models, along with existing data from tests which measure lung capacity and highly detailed x-rays, known as CT scans, the scientists will be able test new therapies, which will enable them to tailor treatments to the individual.

The aim is to use this information to generate an extensive database that will be able to link the characteristics of different airways to a particular treatment in the future, helping health professionals provide personalised treatment for people with COPD and asthma.

These tools will also help scientists predict how the diseases will progress and the effect on the airways, to help monitor the future risk to patients.

Professor Chris Brightling, project lead, said: “Current treatments for COPD and asthma adopt a ‘one size fits all’ approach. People with these respiratory diseases are therefore missing out on the right treatment to help them manage their condition. These patient-specific models will help us monitor the diseases and how they progress, to make current treatments much more specific and targeted to benefit COPD and asthma patients.

Our ability to create a model of the lung using CT scans and other data has advanced greatly along with our ability to measure genes and their activity. We are also at a point in time where computational models have advanced to the point where they can be used to make sense of 1000s of measurements. Now is the time to bring all these elements together to change the way diagnose patients”

Breda Flood, a patient with asthma and board member of European Federation of Allergy and Airways Diseases Patients Association (EFA), said: “This new model will help us to visualise activity in our lungs and see how our illness affects our breathing. By gaining an insight into how specific treatments will work, patients will have a better understanding of how to manage their condition in the future.”

Notes to editors:

EFA-AirPROM release

*AirPROM (Airway Disease PRedicting Outcomes through Patient Specific Computational Modelling)

The project is part of the Virtual Physiological Human Project which aims to help support and progress European research in biomedical modelling and simulation of the human body. For more information, please visit: http://www.vph-noe.eu/ 

Facts on COPD and asthma:

• Asthma affects 300 million people worldwide
• Asthma causes approximately 239,000 deaths worldwide per year
• The total cost of asthma in Europe is estimated to be €17.7 billion per annum
• COPD is predicted to be the 3rd leading cause of death in world by 2030
• 80 million people have moderate–to–severe COPD worldwide
• The annual cost of COPD is estimated to be €38.8billion in Europe

Media contact at EFA:

Susanna Palkonen, Executive Officer, Tel +32 (0)476 373923 Email This email address is being protected from spambots. You need JavaScript enabled to view it. www.efanet.org

Partners involved in the project:

University of Leicester
Helmholtz Zentrum München German Research Center for Environmental Health
University of Amsterdam
Imperial College London
The Queen's University of Belfast
University of Oxford
University of Nottingham
University of Sheffield
GET/ Institute National des Telecommunications, Department ARTEMIS
University of Warwick
Fundacio Privada Parc Cientific de Barcelona
Materialise N.V.
ANSYS UK, Ltd.
Instytut Chemi Bioorganicznej Pan
FluiDA nv
Biomax Informatics AG
European Respiratory Society
BioSci Consulting
Southampton Medical School
University of Catania, Italy
Semmelsweis University
University of Manchester
Universite de la Mediteranee, Marseilles
University Hospital, Umea, Sweden
Karolinska Inst,Sweden
Objet Geometries
University of Ferrara
European Federation of Allergy and Airways Diseases Patients Associations (EFA)
National Research Institute of Tuberculosis and Lung Diseases
Queen Silvia Children's Hospital
National Koranyi Institute
Centre National de Génotypage
University Hospitals Coventry and Warwickshire
European Lung Foundation

Dear Visitor,

for regularly updated information on Covid-19 for allergy and respiratory patients, please consult our Covid-19 resource and information hub.
Stay safe!
The EFA Team